Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hematopoietic Cell Transplantation-Stanford University-systemic lupus erythematosus refers to a specific therapeutic procedure developed at Stanford University for patients with severe, refractory systemic lupus erythematosus (SLE). The protocol (NCT00325741) utilizes an allogeneic hematopoietic cell transplantation (HCT) approach with a non-myeloablative conditioning regimen. This regimen consists of total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (ATG) to deplete the host's autoreactive immune cells without completely destroying the bone marrow. Following conditioning, patients receive an infusion of HLA-matched donor CD34+ hematopoietic stem cells. The goal is to establish stable mixed chimerism, where donor-derived immune cells replace the patient's dysfunctional immune system, potentially leading to long-term remission of life-threatening SLE manifestations in the kidneys, lungs, heart, or central nervous system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hematopoietic Cell Transplantation-Stanford University-systemic lupus erythematosus.